Core Insights - Milestone Scientific Inc. reported continued progress in operational transformation and growth strategy across its dental and medical segments, with a focus on building a leaner organization for sustained growth and improved profitability [1][2]. Financial Performance - For Q3 2025, revenues were approximately $2.4 million, a slight decrease from $2.5 million in Q3 2024, primarily due to lower domestic dental sales, partially offset by higher international dental sales and recurring medical revenue [3]. - Gross profit for Q3 2025 was approximately $1.6 million, or 70% of revenue, compared to $1.8 million, or 73% of revenue, in Q3 2024 [3]. - The operating loss for Q3 2025 was approximately $(1.1) million, an improvement of approximately $0.3 million, or 23%, from $(1.5) million in Q3 2024, attributed to lower selling, general, and administrative expenses [3]. - The net loss for Q3 2025 was approximately $(1.2) million, or $(0.01) per share, compared to a net loss of $(1.5) million, or $(0.02) per share, in Q3 2024 [3]. Year-to-Date Results - For the nine months ended September 30, 2025, revenues were approximately $6.9 million, an increase of approximately $0.3 million, or 5%, from $6.6 million in the same period of 2024, driven by growth in international dental sales and higher recurring revenue from the medical segment [4]. - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, or 71% of revenue, consistent with the previous year [4]. - The operating loss for the nine months ended September 30, 2025, was approximately $(4.6) million, slightly improved from $(4.7) million in the same period of 2024 [4]. - The net loss for the nine months ended September 30, 2025, was approximately $(4.6) million, or $(0.06) per share, compared to a net loss of $(2.7) million, or $(0.03) per share, in the same period of 2024 [4]. Cash Position - As of September 30, 2025, the company reported cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [5]. Strategic Initiatives - The company is expanding its direct sales programs in North America and securing new international registrations for its STA® Single Tooth Anesthesia System, while enhancing its omnichannel digital marketing strategy [2]. - There is growing utilization and recurring revenue from CompuFlo® disposables, with increasing interest from hospitals and international distributors [2]. - The company is advancing its reimbursement strategy for CompuFlo®, focusing on securing Medicare payment-rate assignments and expanding commercial coverage, which are seen as key enablers for broader adoption [2].

ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company’s financial results for the third quarter ended September 30, 2025, as well as the company’s corporate progress and other developments. The conference call will be available via telep ...

Core Viewpoint - Milestone Scientific Inc. will host a conference call to discuss its financial results for Q2 2025 and corporate developments [1] Group 1: Conference Call Details - The conference call is scheduled for 8:00 AM Eastern Time on August 15, 2025 [1] - U.S. callers can dial toll-free 888-506-0062, while international callers can use +1 973-528-0011 with access code 470429 [2] - An audio replay will be available until August 29, 2025, accessible via 877-481-4010 for U.S. callers and +1 919-882-2331 for international callers with access code 52876 [3] Group 2: Company Overview - Milestone Scientific Inc. is a technology-focused medical research and development company specializing in innovative injection technologies for medical, dental, and cosmetic applications [4] - The company’s computer-controlled systems aim to enhance injection precision, efficiency, and patient comfort and safety [4] - The proprietary DPS Dynamic Pressure Sensing Technology is utilized to regulate flow rate and monitor pressure during subcutaneous drug delivery [4]